Epicur Pharma’s Post

Understand heart medications with Cardiobis 💊 As a healthcare professional, understanding the nuances of heart disease medications is crucial for optimising patient care. Cardiobis’s Module 10: Medications and Their Role, led by Dr. Naylin Bissessor, MD, PhD, provides a comprehensive exploration of commonly prescribed medications, their therapeutic roles, and potential side effects. This module emphasises the importance of medication adherence and its impact on patient outcomes, equipping you with the knowledge to better support your patients in managing heart disease effectively. Explore Module 10 at Cardiobis.com to deepen your expertise in cardiovascular pharmacology. #CardiovascularCare #Cardiobis #MedicationsInCardiology

Article published in the Journal of Cardiovascular Pharmacology featuring Professor Salvatore De Rosa, a specialist in Cardiovascular Diseases at #DSMC of Università 'Magna Graecia' di Catanzaro. 🔬📄 "Management of patients treated with oral anticoagulant therapy undergoing percutaneous coronary intervention with stent implantation: the PERSEO Registry" explores the efficacy of anticoagulant therapies in patients undergoing coronary interventions with stent implantation. 📈 In this study, conducted on 1234 patients from February 2018 to February 2022, antithrombotic regimens in patients on oral anticoagulants (OAC) undergoing percutaneous coronary intervention (PCI) were examined. The analysis revealed that the use of direct oral anticoagulants (DOAC) resulted in a lower rate of net adverse clinical events (NACE) compared to vitamin K antagonists (VKA). Additionally, dual antithrombotic therapy (DAT) showed a reduction in major bleedings compared to triple antithrombotic therapy (TAT). 📉 Key results: ➡️ 16% of patients treated with DOAC experienced NACE, compared to 23% of patients on VKA. ➡️ DAT showed fewer major bleedings compared to TAT (2% vs 5%). 🔍 These real-world data highlight the importance of choosing the optimal antithrombotic regimen to improve outcomes in patients on OAC undergoing PCI. #Cardiology #Anticoagulants #PCI #Stent #MedicalResearch #CardiovascularHealth #JournalOfCardiovascularPharmacology

Automated blood culture bottles fully compatible with all fluorescent and colorimetric Automated blood culture systems. Fully compatible, similar results better pricing. #biogenix #diagnostics #pathology #microbiology #BloodCulture #culturemedia #automatedbloodculture #distributor #HealthcareInnovation #laboratoryequipment #medicaldevices #healthtechnology #IVD #laboratorylife #MedicalInnovation #equipment #diagnosis #diagnostictesting #laboratorytesting

GLP1 Receptor Agonists in Weight Loss: Efficacy, Risks, and Benefits This video from Harvard Medical School explores the role of GLP1 receptor agonists (GLP1 RA), such as liraglutide and semaglutide, in managing weight loss. Dr. Lee-Shing Chang discusses FDA-approved medications for weight management, highlighting key studies like SCALE and STEP trials. The efficacy of GLP1 RAs is compared to other treatments, alongside the risks and benefits of using these medications. #WeightLoss #GLP1RA #ObesityTreatment #HarvardMedical #Endocrinology Credit: Lee-Shing Chang Harvard University Brigham and Women's Hospital

Automated blood culture bottles fully compatible with all fluorescent and colorimetric Automated blood culture systems. Fully compatible, similar results better pricing. #biogenix #diagnostics #pathology #microbiology #BloodCulture #culturemediaa #automatedbloodculture #distributor #HealthcareInnovation #laboratoryequipment #medicaldevices #healthtechnology #IVD #laboratorylife #MedicalInnovation #equipment #diagnosis #diagnostictesting #laboratorytesting

The answer to yesterday’s #ClinicalChallenge question is: D. Recombinant ADAMTS13 can rapidly raise the ADAMTS13 activity levels. It was FDA approved for treatment of hereditary thrombotic thrombocytopenic purpura (TTP), and it also may have a role in individuals with immune TTP who have refractory disease and/or cannot receive therapeutic plasma exchange. View the related What's New topic in #UpToDate: https://ow.ly/vJU850TEzPZ #hematology #meded

Tired of tedious hematology tasks slowing you down? Here's a glimpse into how CrelioHealth Hematology Lab Software can supercharge your lab's efficiency! Book Demo Now: https://bit.ly/3jP7hoP #pathology #healthtech #healthcaretips #healthcareworkers #microbiology #biology #MedicalInnovation #labtechnician #patientcare #PatientExperience #patients #microbiologist #laboratorylife #laboratorytesting #laboratorywork #bloodtesting #laboratoryequipment #diagnosticcenter #diagnostics #LabManagement

As AbbVie and NeuroDerm race toward potential Parkinson's disease approvals later this year, the companies presented strong data at last week’s American Academy of Neurology 2024 annual meeting for their respective continuous subcutaneous levodopa infusions. Both companies are developing novel delivery systems that allow 24-hour continuous subcutaneous delivery of their drug candidates, which according to Erela Dana, director of neurology at data analytics firm GlobalData Plc, could “improve the rate of compliance while reducing risk of motor fluctuations and levodopa-induced complications.” NeuroDerm is ahead of AbbVie in the race to U.S. commercialization, but Dana notes that if both products receive FDA approval, real-world evidence and longer-term follow-up data “could provide a competitive edge in the absence of a head-to-head trial.” #biotech #biopharma #ParkinsonsDisease #levodopa

Indeed, thanks Saroja Ramanujan for pointing this out. There is an equally fascinating publication by @Ron Sender, Ron Milo and team on The total mass, number, and distribution of immune cells in the human body: https://lnkd.in/dT-RRHcb . These are fundamental data for developing immuno-oncology therapies where we try to direct the human immune system to fight cancer cells. Intuitively it is clear that in the fight of immune cells against cancer cells it matters what the numbers are. While this is well studied in vitro by exploring the E:T ratio (effector-to-tumor cell ratio) it is much more difficult to translate these findings to human: What is the concentration of immune cells in human tumors? How does it depend on tumor type? How does it vary between patients? How does it change over time? How high does it need to be to effectively destroy the tumor when being activated? I would love to see this work extended from healthy organs to disease in particular tumors.

Vascular Pharmacology just published as a Special Issue on line a compendium of short authoritative papers on Coronary Artery Disease and Myocardial Ischemic Syndromes: From pathobiology to mechanisms, diagnosis and therapy. Here is a link: https://lnkd.in/e3RufPYw #coronaryarterydisease #heartattack #myocardialinfarction #ischemia #cardiology #atherosclerosis #angina